MX2015006710A - Tratamiento de las enfermedades pulmonares. - Google Patents

Tratamiento de las enfermedades pulmonares.

Info

Publication number
MX2015006710A
MX2015006710A MX2015006710A MX2015006710A MX2015006710A MX 2015006710 A MX2015006710 A MX 2015006710A MX 2015006710 A MX2015006710 A MX 2015006710A MX 2015006710 A MX2015006710 A MX 2015006710A MX 2015006710 A MX2015006710 A MX 2015006710A
Authority
MX
Mexico
Prior art keywords
pulmonary disease
treatment
reducing
lung
alleviating
Prior art date
Application number
MX2015006710A
Other languages
English (en)
Spanish (es)
Inventor
Mark Pruzanski
Luciano Adorini
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49753520&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2015006710(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Publication of MX2015006710A publication Critical patent/MX2015006710A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2015006710A 2012-11-28 2013-11-26 Tratamiento de las enfermedades pulmonares. MX2015006710A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261730749P 2012-11-28 2012-11-28
PCT/US2013/072038 WO2014085474A1 (en) 2012-11-28 2013-11-26 Treatment of pulmonary disease

Publications (1)

Publication Number Publication Date
MX2015006710A true MX2015006710A (es) 2016-01-15

Family

ID=49753520

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015006710A MX2015006710A (es) 2012-11-28 2013-11-26 Tratamiento de las enfermedades pulmonares.

Country Status (19)

Country Link
US (3) US20140148428A1 (enExample)
EP (1) EP2925328A1 (enExample)
JP (1) JP6270171B2 (enExample)
KR (1) KR102106186B1 (enExample)
CN (1) CN104853758A (enExample)
AU (1) AU2013352288B2 (enExample)
BR (1) BR112015012312A2 (enExample)
CA (1) CA2891348C (enExample)
CL (1) CL2015001442A1 (enExample)
HK (1) HK1211844A1 (enExample)
IL (1) IL239025B (enExample)
MX (1) MX2015006710A (enExample)
MY (1) MY170802A (enExample)
NZ (1) NZ708501A (enExample)
PH (1) PH12015501108A1 (enExample)
RU (1) RU2693382C2 (enExample)
SG (1) SG11201503697TA (enExample)
TW (1) TWI636786B (enExample)
WO (1) WO2014085474A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3985118A1 (en) 2013-11-22 2022-04-20 MiNA Therapeutics Limited C/ebp alpha short activating rna compositions and methods of use
CN106459136B (zh) * 2014-09-28 2018-06-26 江苏盛迪医药有限公司 一种奥贝胆酸的制备方法
CN107108687B (zh) * 2014-11-19 2019-10-29 Nzp英国有限公司 作为制备类固醇FXR调节剂的中间体的5β-6-烷基-7-羟基-3-酮类固醇
TWI690536B (zh) * 2014-11-19 2020-04-11 英商Ｎｚｐ英國有限公司 化合物（一）
KR102546748B1 (ko) * 2014-11-19 2023-06-22 엔제트피 유케이 리미티드 스테로이드 FXR 조절인자를 제조하기 위한 중간체로서의 6α-알킬-3,7-다이온 스테로이드
CA2968310A1 (en) * 2014-11-19 2016-05-26 NZP UK Limited 6.alpha.-alkyl-6,7-dione steroids as intermediates for the production of steroidal fxr modulators
CN105348365A (zh) * 2014-12-03 2016-02-24 四川百利药业有限责任公司 一种胆酸衍生物及其制备方法、药物组合物和用途
CN105801653B (zh) * 2014-12-30 2018-04-17 苏州晶云药物科技有限公司 奥贝胆酸的晶型a及其制备方法
CZ2015504A3 (cs) * 2015-07-16 2017-01-25 Zentiva, K.S. Krystalické formy obeticholové kyseliny
CN105085597B (zh) * 2015-08-28 2017-03-29 成都百裕制药股份有限公司 一种无定型奥贝胆酸的制备方法
EP3353189A4 (en) 2015-09-24 2019-06-19 Intercept Pharmaceuticals, Inc. METHOD AND INTERMEDIATE PRODUCTS FOR THE PREPARATION OF GALLENIC ACID DERIVATIVES
AR106293A1 (es) * 2015-10-07 2018-01-03 Intercept Pharmaceuticals Inc Moduladores del receptor x farnesoide
CN106589039B (zh) * 2015-10-15 2019-12-17 苏州朗科生物技术股份有限公司 一种奥贝胆酸的制备方法及相关化合物
CN106589038A (zh) * 2015-10-15 2017-04-26 重庆医药工业研究院有限责任公司 一种制备3α,7α-二羟基-6α-乙基-5β-胆烷酸的方法
CN106668027A (zh) * 2015-11-05 2017-05-17 中美华世通生物医药科技（武汉）有限公司 奥贝胆酸药物组合物及其制备方法
CN105399793A (zh) * 2015-12-24 2016-03-16 北京康立生医药技术开发有限公司 一种胆烷酸的制备方法
WO2017137931A1 (en) 2016-02-10 2017-08-17 Dr. Reddy’S Laboratories Limited Amine salt of obeticholic acid
TW201735928A (zh) * 2016-03-31 2017-10-16 大日本住友製藥股份有限公司 溶出性優異之口服製劑
US10369160B2 (en) 2016-04-13 2019-08-06 Intercept Pharmaceuticals, Inc. Methods of treating cancer
GB201608777D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Compounds
GB201608776D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Methods and compounds
CN109415405A (zh) * 2016-06-01 2019-03-01 雷迪博士实验室有限公司 制备奥贝胆酸的方法
CN106046095B (zh) * 2016-06-06 2017-02-22 南京理工大学 奥贝胆酸的合成方法
CA3038534A1 (en) * 2016-09-30 2018-04-05 Intercept Pharmaceuticals, Inc. Crystalline forms of a bile acid derivative
CN108117579A (zh) * 2016-11-29 2018-06-05 昆明积大制药股份有限公司 奥贝胆酸及其中间体的制备方法
TW201832768A (zh) * 2017-03-07 2018-09-16 英特賽普醫藥品公司 治療癌症的方法
US11162099B2 (en) 2017-09-08 2021-11-02 Mina Therapeutics Limited HNF4A saRNA compositions and methods of use
KR20190030805A (ko) * 2017-09-14 2019-03-25 경상대학교산학협력단 폐고혈압 예방 또는 치료용 흡입제, 및 이의 투여방법
WO2019085963A1 (zh) * 2017-11-02 2019-05-09 正大天晴药业集团股份有限公司 一种胆酸类化合物的制备方法
JP7555327B2 (ja) 2018-07-25 2024-09-24 ノバルティス アーゲー Ｎｌｒｐ３インフラマソーム阻害剤
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
WO2021044351A1 (en) 2019-09-06 2021-03-11 Novartis Ag Methods of treating liver disease using lta4h inhibitors
WO2021071837A1 (en) 2019-10-07 2021-04-15 Kallyope, Inc. Gpr119 agonists
TW202140440A (zh) 2020-02-28 2021-11-01 美商克力歐普股份有限公司 Gpr40激動劑
CN113318114B (zh) * 2020-02-28 2023-02-17 广州市赛普特医药科技股份有限公司 小分子化合物在治疗肺上皮细胞损伤和/或血管内皮细胞损伤介导的疾病中的用途
UY39222A (es) 2020-05-19 2021-11-30 Kallyope Inc Activadores de la ampk
AU2021297323A1 (en) 2020-06-26 2023-02-16 Kallyope, Inc. AMPK activators
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2064336B (en) 1979-12-06 1984-03-14 Glaxo Group Ltd Device for dispensing medicaments
US4353656A (en) 1980-10-14 1982-10-12 Xerox Corporation Moving coil, multiple energy print hammer system including a closed loop servo
CY1492A (en) 1981-07-08 1990-02-16 Draco Ab Powder inhalator
GB2169265B (en) 1982-10-08 1987-08-12 Glaxo Group Ltd Pack for medicament
GB2129691B (en) 1982-10-08 1987-08-05 Glaxo Group Ltd Devices for administering medicaments to patients
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
FR2585563B1 (fr) 1985-07-30 1993-11-12 Glaxo Group Ltd Dispositif pour administrer des medicaments a des patients
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
US5977095A (en) * 1993-03-09 1999-11-02 University Of Utah Research Foundation Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and respiratory distress syndrome
EP0813490B1 (en) 1995-03-10 2000-07-12 Minnesota Mining And Manufacturing Company Aerosol valves
GB9700226D0 (en) 1997-01-08 1997-02-26 Glaxo Group Ltd Inhalation device
US6632666B2 (en) 2000-01-14 2003-10-14 Biolife Solutions, Inc. Normothermic, hypothermic and cryopreservation maintenance and storage of cells, tissues and organs in gel-based media
ES2248581T3 (es) 2001-03-12 2006-03-16 Intercept Pharmaceuticals, Inc. Esteroides como agonistas de fxr.
WO2005032549A1 (en) * 2003-09-26 2005-04-14 Smithkline Beecham Corporation Compositions and methods for treatment of fibrosis
PT2712617T (pt) * 2004-03-12 2017-02-13 Intercept Pharmaceuticals Inc Tratamento de fibrose usando ligandos fxr
ITMI20050912A1 (it) 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
CA2656320C (en) 2006-06-27 2015-04-28 Intercept Pharmaceuticals, Inc. Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated diseases or conditions
KR101237623B1 (ko) * 2006-06-29 2013-02-26 에프. 호프만-라 로슈 아게 벤즈이미다졸 유도체, 이의 제조방법, ｆｘｒ 작용물질로서이의 용도, 및 이를 함유하는 약학 제제
AU2009276507B2 (en) * 2008-07-30 2015-11-19 Intercept Pharmaceuticals, Inc. TGR5 modulators and methods of use thereof
CN106380502A (zh) * 2008-11-19 2017-02-08 英特塞普特医药品公司 G蛋白偶联受体5(tgr5)调节剂及其使用方法
EP2379081B1 (en) * 2008-12-19 2013-03-20 Royal College of Surgeons in Ireland Treatment of diarrhoea
BR112012004284B8 (pt) * 2009-08-25 2021-05-25 Ahab Sheps Jonathan ácidos biliares poli-hidroxilados para tratamento de transtornos biliares
US9416151B2 (en) * 2010-08-25 2016-08-16 Lurong ZHANG Use of glycyrrhetinic acid, glycyrrhizic acid and related compounds for prevention and/or treatment of pulmonary fibrosis
CA3047776C (en) * 2012-06-19 2022-10-18 Intercept Pharmaceuticals, Inc. Preparation, uses and solid forms of obeticholic acid

Also Published As

Publication number Publication date
BR112015012312A2 (pt) 2017-07-11
KR20150089052A (ko) 2015-08-04
CA2891348C (en) 2020-04-28
NZ708501A (en) 2019-03-29
PH12015501108B1 (en) 2015-08-17
MY170802A (en) 2019-08-28
TW201434469A (zh) 2014-09-16
CA2891348A1 (en) 2014-06-05
CN104853758A (zh) 2015-08-19
SG11201503697TA (en) 2015-06-29
RU2015122027A (ru) 2017-01-10
IL239025A0 (en) 2015-07-30
EP2925328A1 (en) 2015-10-07
US20180064729A1 (en) 2018-03-08
CL2015001442A1 (es) 2015-08-28
JP6270171B2 (ja) 2018-01-31
HK1211844A1 (en) 2016-06-03
US20160213689A1 (en) 2016-07-28
AU2013352288A1 (en) 2015-06-04
WO2014085474A1 (en) 2014-06-05
JP2016500111A (ja) 2016-01-07
TWI636786B (zh) 2018-10-01
IL239025B (en) 2021-04-29
US20140148428A1 (en) 2014-05-29
RU2693382C2 (ru) 2019-07-02
AU2013352288B2 (en) 2017-11-23
KR102106186B1 (ko) 2020-05-04
PH12015501108A1 (en) 2015-08-17

Similar Documents

Publication Publication Date Title
PH12015501108B1 (en) Treatment of pulmonary disease
IN2015DN02573A (enExample)
IN2015DN01156A (enExample)
IN2014DN09434A (enExample)
EA201391615A1 (ru) Дейтерированные потенциаторы cftr
IN2014DN09173A (enExample)
MY178621A (en) Deuterated cftr potentiators
MY184306A (en) Compounds for the treatment and prophylaxis of respiratory syncytial virus disease
UA109868C2 (ru) Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)
WO2012062925A3 (en) Compounds and methods for treating pain
PH12014500075A1 (en) Pharmaceutical composition, methods for treating and uses thereof
MX2015008187A (es) Inhibidores de alk deuterados.
MX350745B (es) El uso de un compuesto de carbamoilo para el tratamiento del sindrome de fibromialgia.
UA117032C2 (uk) Селективний інгібітор фосфатидилінозитол-3-кінази-гамма
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
JO3510B1 (ar) استخدام جلايكوبيرولات لعلاج عدم انتظام دقات القلب
MX2013013281A (es) Uso de la inhibicion de la catepsina k para el tratamiento y/o profilaxis de hipertension pulmonar y/o insuficiencia cardiaca.
SG10201807318RA (en) Methods for treating chronic obstructive pulmonary disease using benralizumab
EP2585067A4 (en) COMPOUND FOR THE TREATMENT OF ENTEROVIRUS
MX2014003701A (es) Compuestos para el tratamiento y profilaxis de enfermedad por el virus sincitial respiratorio.
WO2014145236A3 (en) The use of sdf-1 to mitigate scar formation
WO2013117503A3 (en) Pi3k inhibitors for treating fibrotic diseases
MX2014014814A (es) Composicion farmaceutica para el tratamiento de inflamacion y dolor.
PH12014500577A1 (en) Sulfonic acid salts of heterocyclylamide-substituted imidazoles
PH12015501210A1 (en) Use of pidotimod to treat psoriasis

Legal Events

Date Code Title Description
FG Grant or registration